Biontech Se Stock Analysis

BioNTech Stock Analysis Notes

About 57.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.21. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioNTech SE has Price/Earnings To Growth (PEG) ratio of 0.04. The entity recorded a loss per share of 2.84. The firm last dividend was issued on the 2nd of June 2022. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Biontech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3082 people. For more info on BioNTech SE please contact Ugur MD at 49 6131 9084 or go to https://www.biontech.de.

BioNTech SE Investment Alerts

BioNTech Largest EPS Surprises

View All Earnings Estimates

BioNTech Environmental, Social, and Governance (ESG) Scores

BioNTech Stock Institutional Investors

Note, although BioNTech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

BioNTech Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 26.85 B.

BioNTech Profitablity

The company has Profit Margin (PM) of (0.18) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.02) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.02.

Management Efficiency

BioNTech SE has return on total asset (ROA) of (0.023) % which means that it has lost $0.023 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0304) %, meaning that it created substantial loss on money invested by shareholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.03 in 2026. Return On Capital Employed is likely to rise to -0.06 in 2026. At this time, BioNTech's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.1 B in 2026, whereas Non Currrent Assets Other are likely to drop slightly above 37.7 M in 2026.

Technical Drivers

As of the 18th of February 2026, BioNTech shows the Risk Adjusted Performance of 0.0098, mean deviation of 1.74, and Downside Deviation of 2.53. BioNTech SE technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

BioNTech SE Price Movement Analysis

BioNTech Outstanding Bonds

BioNTech Predictive Daily Indicators

BioNTech Corporate Filings

BioNTech Forecast Models

BioNTech's time-series forecasting models are one of many BioNTech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioNTech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

BioNTech Bond Ratings

BioNTech SE financial ratings play a critical role in determining how much BioNTech have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for BioNTech's borrowing costs.

BioNTech SE Debt to Cash Allocation

BioNTech SE currently holds 254.2 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. BioNTech SE has a current ratio of 5.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BioNTech's use of debt, we should always consider it together with its cash and equity.

BioNTech Total Assets Over Time

BioNTech Assets Financed by Debt

The debt-to-assets ratio shows the degree to which BioNTech uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

BioNTech Debt Ratio

1.23

It appears most of the BioNTech's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the BioNTech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of BioNTech, which in turn will lower the firm's financial flexibility.

BioNTech Corporate Bonds Issued

BioNTech Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how BioNTech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioNTech shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioNTech. By using and applying BioNTech Stock analysis, traders can create a robust methodology for identifying BioNTech entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BioNTech analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BioNTech analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

BioNTech SE stock analysis indicators help investors evaluate how BioNTech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BioNTech shares will generate the highest return on investment. By understating and applying BioNTech stock analysis, traders can identify BioNTech position entry and exit signals to maximize returns.

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.